In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Dura Pharma gets rights to BMS' Maxipime and Azactam

Executive Summary

Dura Pharmaceuticals (developer and marketer of prescription products for respiratory conditions) has received exclusive US distribution rights from BMSfor its Maxipime IV/IM (cefepime HCl) and Azactam IV/IM (aztreonam).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Marketing (Licensing)

Related Companies